Distal hereditary motor neuropathy

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

No FDA or trial events recorded yet for Distal hereditary motor neuropathy.

Financial Assistance

4 programs

FINANCIAL LANDSCAPE SUMMARY

4

Total programs

4

Open now

Patient Assistance Programs4

Spinraza

Biogen Inc.

OpenContact for detailsApply ↗

Zolgensma

Novartis Gene Therapies, Inc.

OpenContact for detailsApply ↗

ITVISMA

Novartis Gene Therapies, Inc.

OpenContact for detailsApply ↗

EVRYSDI

Genentech, Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

4 FDA-approved

ITVISMA

(ONASEMNOGENE ABEPARVOVEC-BRVE)Orphan drug

Novartis Gene Therapies, Inc.

Approved Nov 2025FDA label ↗

EVRYSDI

(RISDIPLAM)Orphan drug

Genentech, Inc.

Approved Aug 2020FDA label ↗

Zolgensma

(ONASEMNOGENE ABEPARVOVEC-XIOI)Orphan drug

Novartis Gene Therapies, Inc.

Approved May 2019FDA label ↗

Spinraza

(NUSINERSEN)Orphan drug

Biogen Inc.

Approved Dec 2016FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Distal hereditary motor neuropathy.
Search all trials →
Search clinical trials for Distal hereditary motor neuropathy

Recent News & Research

1 article
Lancet NeurologySep 30, 2025

Zolgensma Long-Term Data: 5-Year Outcomes in SMA

Five-year follow-up of Zolgensma in SMA type 1 shows patients maintaining motor milestones with no new safety signals.

Read ↗

Browse all Distal hereditary motor neuropathy news →

Specialist Network

Top 6 by expertise

View all Distal hereditary motor neuropathy specialists →

Quick Actions